title: A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK. graham.collins@ouh.nhs.uk.
authors.forename: Graham P
authors.initials: GP
authors.lastname: Collins
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
authors.forename: Toby A
authors.initials: TA
authors.lastname: Eyre
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
authors.forename: Kim M
authors.initials: KM
authors.lastname: Linton
authors.affiliation: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
authors.forename: John
authors.initials: J
authors.lastname: Radford
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
authors.forename: Grant D
authors.initials: GD
authors.lastname: Vallance
authors.affiliation: Department of Cellular Pathology, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Oxford, UK.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Soilleux
authors.affiliation: Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
authors.forename: Chris
authors.initials: C
authors.lastname: Hatton
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010755:Organophosphates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: C520647:2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; D000970:Antineoplastic Agents; D010755:Organophosphates; D047428:Protein Kinase Inhibitors; D011799:Quinazolines
keywords: AZD1152; Aurora B kinase; barasertib; diffuse large B-cell lymphoma; lymphoid malignancies